BioLargo, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BioLargo, Inc. innovates, engineers, and markets a range of proprietary technologies. The company’s solutions address critical environmental issues, including per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater treatment, industrial odor and volatile organic compound (VOC) management, air quality improvement, and infection control. With a foundation of extensive research and development, it holds numerous issued patents, cultivates a robust product pipeline, and offers comprehensive environmental engineering services. Among its offerings are the Aqueous Electrostatic Concentrator (AEC) system, designed for efficient PFAS removal from water, and the Advanced Oxidation System (AOS), which rapidly eliminates pathogens and complex contaminants. Its CupriDyne Clean industrial products are formulated to neutralize challenging odors and VOCs across various industrial environments. The company also develops advanced wound care and surgical irrigation products through its Clyra Medical Technologies subsidiary, including the ViaCLYR™ Wound Irrigation Solution. Additionally, BioLargo is advancing its Cellinity Liquid Sodium Battery technology for long-duration energy storage. BioLargo, Inc. was established in 1991 and maintains its operations in Westminster, California.
BioLargo Engineering Unit Awarded $1.4 Million in U.S. Air Force Environmental Contract Renewals
BioLargo, Inc. (BLGO) Shareholder/Analyst Call Transcript
BioLargo Subsidiary Clyra Medical Signs Exclusive Distribution Agreement with Al- Hikma FZCO for ViaCLYR(TM) Across the Middle East, North Africa, and Adjacent Markets
BioLargo Signs Memorandum of Understanding with Aquatech to Accelerate Commercialization of PFAS Treatment Technology
BioLargo to Participate in a Town Hall Meeting Hosted by the BioLargo Shareholder Community on Discord on May 5, 2026
BioLargo (NASDAQ:BLGO) versus Global Partner Acquisition Corp II (NASDAQ:GPAC) Critical Survey
Analyzing BioLargo (NASDAQ:BLGO) and Global Partner Acquisition Corp II (NASDAQ:GPAC)
BioLargo Engineering, Science & Technologies Awarded $1.2 Million Contract to Design Pilot-Scale Minerals Processing Facility for Resource Recovery
BioLargo CEO Dennis Calvert to Present Global Environmental Leadership Award to Robert Bilott at Nassau County PFAS Forum
BioLargo, Inc. (BLGO) Q4 2025 Earnings Call Transcript
BioLargo Reports Annual 2025 Operating and Financial Results
BioLargo Q4 2025 and Year End Earnings Results Webcast and Conference Call on Thursday, March 5th, 2026 - 12:00 PM Eastern Time
BioLargo Subsidiary Clyra Medical Highlights Key Opinion Leader Presentation of Exceptional ViaCLYR(TM) Clinical Results at Leading Wound Care Symposium
BioLargo Subsidiary Clyra Medical Technologies Secures First Stocking Order with Advanced Solution for ViaCLYR(TM) Wound Irrigation Solution
BioLargo Installs AEC PFAS Treatment System at Lake Stockholm, New Jersey
BioLargo to Present at Sidoti's Micro-Cap Virtual Conference on Thursday January 22nd at 1pm EST
BioLargo Reflects on 2025 Progress and Positions for the Next Phase of Global Infrastructure, Environmental, and Medical Innovation
BioLargo Subsidiary BEST Featured in Chemical Engineering Magazine for PFAS Breakthrough
BioLargo to Present at NobleCon's 21st Annual Emerging Growth Equity Conference, Dec. 2-3, 2025
BioLargo Reports Q3 2025 Operating and Financial Results